Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trialAnn. Rheum. Dis 2022 Jul 04;[EPub Ahead of Print], D van der Heijde, X Baraliakos, J Sieper, A Deodhar, RD Inman, H Kameda, X Zeng, Y Sui, X Bu, AL Pangan, P Wung, IH Song
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.